MYCN and medulloblastoma: Amplification of the MYC transcription factor family member MYCN drives a range of solid tumours including medulloblastoma, rhabdomyosarcoma, osteosarcoma, Wilms tumour, small cell lung cancer and retinoblastoma, with MYCN overexpression associated with poorer prognoses (Rickman Schulte and Eilers, 2018).